Loading
A phase 1/2 trial of SLOG + Allogeneic NK cell in pancreatic ductal adenocarcinoma and biliary tract cancer, run by Medigen Biotechnology Corporation, now recruiting.
Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients is a phase 1/2 interventional study registered as NCT06730009 by Medigen Biotechnology Corporation, with 42 participants planned, started 2024-10-21 and due to reach its primary completion in 2029-01-31. Interventions recorded: SLOG + Allogeneic NK cell and SLOG chemotherapy.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma), Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/